Onesource Specialty Pharma Ltd.

“Onesource Specialty Pharma combines every attribute of a permanent capital loss candidate: a 1,006x trailing P/E on minimal earnings, debt-to-equity of 21.9x, no independently verifiable competitive moat, and a governance structure characteristic of high-risk Indian promoter-run micro-caps. The market tailwind from India's CDMO growth is real but irrelevant to a company that cannot demonstrably capture it. Even on the optimistic forward P/E of 48x, the stock prices in a full earnings step-change that has yet to materialize, leaving zero margin of safety and substantial downside on a probability-weighted basis. No position is warranted at any price until audited financials, regulatory approvals, and governance track record can be independently verified.”